<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04036682</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-081-001</org_study_id>
    <nct_id>NCT04036682</nct_id>
  </id_info>
  <brief_title>A Phase 1/2a Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cullinan Pearl</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cullinan Oncology, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CLN-081-101 is a Phase 1/2a, open label, multi-center study of CLN-081 in patients with NSCLC&#xD;
      (non small cell lung cancer) harboring EGFR (epidermal growth factor receptor) exon 20&#xD;
      insertion mutations, to determine the maximum tolerated dose (MTD) and recommended Phase 2&#xD;
      dose (RP2D), as well as to evaluate preliminary efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2a, open-label, multicenter, first-in-human trial to evaluate the safety&#xD;
      and tolerability, PK, PD, and preliminary efficacy of CLN-081 in patients with non-small cell&#xD;
      lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion&#xD;
      mutations.&#xD;
&#xD;
      This trial is divided into three parts: Phase 1 Dose Escalation, Phase 1 Dose Expansion, and&#xD;
      Phase 2a Dose Expansion.&#xD;
&#xD;
      The objectives of the dose escalation part are to determine the safety, tolerability, MTD,&#xD;
      recommended Phase 2 dose (RP2D), and to evaluate the anti-tumor activity of orally&#xD;
      administered CLN-081 monotherapy. Additional objectives are to determine the pharmacokinetic&#xD;
      (PK) profile of CLN-081 and CLN-081's activity in patients with known central nervous system&#xD;
      (CNS) disease.&#xD;
&#xD;
      CLN-081 will be dosed once daily (QD) and twice daily (BID).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2019</start_date>
  <completion_date type="Anticipated">March 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All Cohorts: The rate and severity of treatment emergent AEs.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All Cohorts: The rate and severity of DLTs.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All Cohorts: Incidence of safety laboratory assessment abnormalities.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All Cohorts: Incidence of abnormalities in vital signs.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2a Dose Expansion Cohorts: Overall response rate (ORR)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Escalation and Dose Expansion Cohorts: ORR</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Escalation and Dose Expansion Cohorts: DOR (duration of response).</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Escalation and Dose Expansion Cohorts: DCR (disease control rate)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Escalation and Dose Expansion Cohorts: PFS (progression free survival)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Escalation and Dose Expansion Cohorts: OS (overall survival)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Assessment of maximum concentration (Cmax)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Assessment of area under curve (AUC)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Assessment of time to maximum concentration (tmax)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Assessment of terminal half-life (t1/2)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Assessment of mean residence time (MRT)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>EGFR Exon 20 Mutation</condition>
  <arm_group>
    <arm_group_label>Phase 1 Dose Escalation (Accelerated Titration)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLN-081 BID in single patient dose escalation cohorts enrolling NSCLC patients with EGFR exon 20 insertion mutations that either have received or never received prior EGFR TKIs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Dose Escalation (Rolling Six)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLN-081 QD or BID in Rolling Six dose escalation cohorts enrolling NSCLC patients with EGFR exon 20 insertion mutations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Dose Expansion(s)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLN-081 BID in expansion cohorts that may be opened at doses that meet pre-specified efficacy and safety criteria in Rolling Six cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a Dose Expansion(s)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLN-081 QD or BID in expansion cohorts that may be opened at doses that meet pre-specified efficacy and safety criteria in Phase 1 Dose Escalation cohorts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLN-081</intervention_name>
    <description>CLN-081 tablets</description>
    <arm_group_label>Phase 1 Dose Escalation (Accelerated Titration)</arm_group_label>
    <arm_group_label>Phase 1 Dose Escalation (Rolling Six)</arm_group_label>
    <arm_group_label>Phase 1 Dose Expansion(s)</arm_group_label>
    <arm_group_label>Phase 2a Dose Expansion(s)</arm_group_label>
    <other_name>TAS6417</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed recurrent, metastatic NSCLC.&#xD;
&#xD;
          2. Documented EGFR exon 20 insertion mutation demonstrated by a test routinely used by&#xD;
             each institution and performed in a CLIA-certified or equivalent laboratory.&#xD;
&#xD;
          3. Prior treatment in the recurrent/metastatic disease setting including:&#xD;
&#xD;
               1. A platinum-based chemotherapy regimen (or other chemotherapy regimen if&#xD;
                  platinum-based chemotherapy is contra-indicated)&#xD;
&#xD;
               2. Any other approved standard therapy that is available to the patient, unless this&#xD;
                  therapy is contraindicated, intolerable to the patient, or is declined by the&#xD;
                  patient. In the case of a patient declining such therapy, documentation that the&#xD;
                  patient has been informed and declined should be documented in the medical&#xD;
                  record.&#xD;
&#xD;
          4. Measurable disease by RECIST 1.1.&#xD;
&#xD;
          5. Age ≥ 18 years.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.&#xD;
&#xD;
          7. Ability to take pills by mouth.&#xD;
&#xD;
          8. Have the following laboratory values:&#xD;
&#xD;
               1. Serum creatinine &lt; 1.5 × ULN or if higher than normal range, calculated&#xD;
                  creatinine clearance (CrCl) must be ≥ 50 mL/min/1.73 m2 (by Cockroft-Gault&#xD;
                  formula); actual body weight must be used for CrCl unless BMI &gt; 30 kg/m2 then&#xD;
                  lean body weight must be used.&#xD;
&#xD;
               2. Total bilirubin ≤ 1.5 × ULN unless prior history of Gilbert's syndrome.&#xD;
&#xD;
               3. Aspartate transaminase and alanine transaminase ≤ 2.5 × ULN, or ≤ 5 × ULN if due&#xD;
                  to liver involvement by tumor.&#xD;
&#xD;
               4. Hemoglobin ≥ 9.0 g/dL.&#xD;
&#xD;
               5. Platelets ≥ 100 × 109 cells/L.&#xD;
&#xD;
               6. Absolute neutrophil count ≥ 1.5 ×109 cells/L.&#xD;
&#xD;
          9. Ability to understand and the willingness to sign a written informed consent document&#xD;
             and comply with study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior Exon 20 Patients Only&#xD;
&#xD;
             a. No Prior treatment with an EGFR exon 20 insertion-targeting drug (e.g., poziotinib,&#xD;
             TAK788, tarloxotinib, JNJ-61186372).&#xD;
&#xD;
          2. Rolling Six, Phase 1 Expansion, and Phase 2a Expansion Patients Only&#xD;
&#xD;
             a. Prior treatment with an EGFR exon 20 insertion-targeting drug (e.g., poziotinib,&#xD;
             TAK788, tarloxotinib, JNJ-61186372).&#xD;
&#xD;
          3. All Patients&#xD;
&#xD;
             Treatment with any of the following:&#xD;
&#xD;
               1. An EGFR tyrosine kinase inhibitors (TKIs) ≤ 8 days or 5x the terminal phase&#xD;
                  elimination half-lives, whichever is longer, prior to the first dose of study&#xD;
                  drug on C1D1&#xD;
&#xD;
               2. Systemic anticancer treatment (excluding EGFR-TKIs as described above) ≤ 14 days&#xD;
                  prior to the first dose of study drug on C1D1.&#xD;
&#xD;
               3. Radiotherapy &lt; 28 days and palliative radiation ≤ 14 days prior to the first dose&#xD;
                  of study drug on C1D1. If irradiated, lesions must have demonstrated clear-cut&#xD;
                  progression prior to to being eligible for evaluation as target lesions.&#xD;
&#xD;
               4. Immunotherapy ≤ 28 days prior to the first dose of study drug on C1D1.&#xD;
&#xD;
               5. Major surgery (excluding placement of vascular access) ≤ 28 days of the first&#xD;
                  dose of study drug on C1D1.&#xD;
&#xD;
          4. Have any unresolved toxicity of Grade ≥ 2 from previous anti-cancer treatment, except&#xD;
             for alopecia and skin pigmentation. Patients with chronic, but stable Grade 2&#xD;
             toxicities may be allowed to enroll after agreement between the Investigator and&#xD;
             Sponsor.&#xD;
&#xD;
          5. Have known or suspected brain metastases or spinal cord compression, unless the&#xD;
             condition has been asymptomatic, treated with surgery and/or radiation, and has been&#xD;
             stable without requiring escalating corticosteroids or anti-convulsant medications for&#xD;
             at least four weeks prior to the first dose of study drug on C1D1.&#xD;
&#xD;
          6. Prior therapy with CLN-081.&#xD;
&#xD;
          7. Known hypersensitivity to CLN-081 or any drugs similar in structure or class.&#xD;
&#xD;
          8. Cardiac conditions as follows: Patient has a history of congestive heart failure (CHF)&#xD;
             Class III/IV according to the New York Heart Association (NYHA) Functional&#xD;
             Classification or serious cardiac arrhythmias requiring treatment.&#xD;
&#xD;
          9. Past medical history of interstitial lung disease, drug-induced interstitial lung&#xD;
             disease, radiation pneumonitis which required steroid treatment, or any evidence of&#xD;
             clinically active interstitial lung disease.&#xD;
&#xD;
         10. Resting corrected QT interval (QTc) &gt; 470 msec.&#xD;
&#xD;
         11. Patient is unable to take drugs orally due to disorders or diseases that may affect&#xD;
             gastrointestinal function, such as inflammatory bowel diseases (e.g., Crohn's disease,&#xD;
             ulcerative colitis) or malabsorption syndrome, or procedures that may affect&#xD;
             gastrointestinal function, such as gastrectomy, enterectomy, or colectomy.&#xD;
&#xD;
         12. Have any condition or illness that, in the opinion of the investigator, might&#xD;
             compromise patient safety or interfere with the evaluation of the safety of the drug.&#xD;
&#xD;
         13. Pregnant or lactating women; women of child-bearing potential (WOCBP) must have a&#xD;
             negative serum pregnancy test ≤ 7 days prior to receiving study drug on C1D1. WOCBP&#xD;
             and males with partners of child-bearing potential must agree to use adequate birth&#xD;
             control throughout their participation and for six months following the last dose of&#xD;
             study treatment.&#xD;
&#xD;
         14. History of another primary malignancy ≤ 2 years prior to starting study drug on C1D1,&#xD;
             except for adequately treated basal or squamous cell carcinoma of the skin or cancer&#xD;
             of the cervix in situ.&#xD;
&#xD;
         15. Uncontrolled intercurrent illness including, but not limited to, uncompensated&#xD;
             respiratory, cardiac, hepatic, or renal disease, active infection (including HIV and&#xD;
             active clinical tuberculosis), or renal transplant; ongoing or active infection,&#xD;
             symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia,&#xD;
             active peptic ulcer disease or gastritis, or psychiatric illness/social situations&#xD;
             that would limit compliance with study requirements.&#xD;
&#xD;
         16. For patients with a history of hepatitis B, active infection as defined by a positive&#xD;
             HBsAg test and detectable HBV DNA. Patients ineligible due to detectable levels of HBV&#xD;
             DNA at baseline may be rescreened for enrollment if their HBV DNA levels become&#xD;
             undetectable after treatment with antiviral agents, and upon agreement between the&#xD;
             investigator and Sponsor.&#xD;
&#xD;
         17. For patients with a history of hepatitis C, active infection as defined by a reactive&#xD;
             HCV antibody test and detectable HCV RNA.&#xD;
&#xD;
         18. Active bleeding disorders.&#xD;
&#xD;
         19. Is, in the Investigator's opinion, unable or unwilling to comply with the trial&#xD;
             procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zosia Piotrowska, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Myles Clancy</last_name>
    <phone>617-410-4650</phone>
    <email>CLN081001trial@cullinanoncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffani Gosha</last_name>
      <email>tgosha@coh.org</email>
    </contact>
    <investigator>
      <last_name>Marianna Koczywas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Shores Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Hamilton</last_name>
      <phone>562-590-0345</phone>
      <phone_ext>380</phone_ext>
      <email>christinah@pacshoresoncology.com</email>
    </contact>
    <investigator>
      <last_name>Danny Nguyen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jonathan W Riess, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AdventHealth</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosangela Spear</last_name>
      <email>rosangela.spear@adventhealth.com</email>
    </contact>
    <investigator>
      <last_name>Mark Socinski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zosia Piotrowska, MD</last_name>
    </contact>
    <contact_backup>
      <email>zofia.piotrowska@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Zosia Piotrowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cindy Fogel, PhD, CCRF</last_name>
      <phone>314-362-1518</phone>
      <email>clfogal@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Saiama Waqar, MBBS, MSCI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjara Begum</last_name>
      <email>Marjana.begum@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Vamsi Velcheti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-608-3912</phone>
      <email>YuH@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Greg Reily, MD, PhD</last_name>
      <phone>646-888-4199</phone>
      <email>rielyg@mskcc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Helena Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Greg Riely, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Rachel E Sanborn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Godwin</last_name>
      <email>woodrufk@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alex Leitner</last_name>
      <email>leitnera@musc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Wrangle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alex Spira, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Zheng Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hong Kong University - Shenzhen Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518057</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Victor Ho-Fun Lee, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hong Kong University - Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Ho-Fun Lee, MBBS</last_name>
      <email>vhflee@hku.hk</email>
    </contact>
    <investigator>
      <last_name>Victor Ho-Fun Lee, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute (NKI)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Egbert Smit, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <email>e.smit@nki.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Egbert Smit, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Singapore Clinical Research Institute</name>
      <address>
        <city>Singapore</city>
        <zip>138669</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Yan</last_name>
      <email>mei_yan_pang@nuhs.edu.sg</email>
    </contact>
    <investigator>
      <last_name>Ross Soo, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Tan SW, MBBS, PhD</last_name>
      <email>clinical.trials@nccs.com.sg</email>
    </contact>
    <investigator>
      <last_name>Daniel Tan SW, MBBS, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James Chin-Hsin Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2019</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>EGFR</keyword>
  <keyword>Exon 20 insertions</keyword>
  <keyword>CLN-081</keyword>
  <keyword>TAS6417</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

